NCT07051538View on ClinicalTrials.gov

A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

SHR-1139 Injections

SHR-1139 injections.

DRUG

SHR-1139 Injections Placebo

SHR-1139 injections placebo

Trial Locations (1)

200031

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT07051538 - A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter